Cite
HARVARD Citation
Rinke, A. et al. (n.d.). 1311PDHealth-related quality of life (HRQoL) for octreotide long-acting (oct l-a) vs. placebo (PBO) in patients (pts) with metastatic midgut neuroendocrine tumors (mmNETs) in the phase IIIb PROMID trial. Annals of oncology. p. . [Online].